Shanghai Zhida Technology Development's (HKG:2650) shares will be added to the FTSE Global Equity Index Series following the latest quarterly review, according to a Tuesday Hong Kong bourse filing.
Shares of the EV charging systems maker were up nearly 3% in Wednesday afternoon trade.
The company said its shares will be included in the FTSE Global Equity Index Series Micro Cap and FTSE Total-Cap Index.
The index changes will take effect after the market closes on June 19.
Changchun High-Tech Industry's (SHE:000661) subsidiary, Changchun GeneScience Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of GenSci144 tablets, according to a Shenzhen bourse filing on Wednesday.The drug will be tested as a treatment for phenylketonuria, a genetic disorder caused by defects in the phenylalanine hydroxylase gene, leading to hyperphenylalaninemia.The Chinese drug manufacturer's shares dropped 2% during the afternoon trade.
Haisco Pharmaceutical (SHE:002653) obtained approval from China's National Medical Products Administration for the clinical trials of the HSK44459 cream, according to a Wednesday filing on the Shenzhen bourse.The cream will be tested as a treatment for psoriasis and atopic dermatitis.
Star Sports Medicine (HKG:1609) subscribed to two wealth management products with a combined principal amount of 190 million yuan, according to a Tuesday Hong Kong bourse filing.Shares of the medical device company were up nearly 3% in Wednesday afternoon trade.The company subscribed to an 80 million yuan wealth management product issued by Agricultural Bank of China (HKG:1288, SHA:601288) on May 26 and a 110 million yuan product issued by Bank of Beijing on May 11, using its own funds.The company said the subscriptions were part of its routine treasury management of idle funds and followed the maturity of earlier wealth management and structured deposit investments this month.